A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
A phase 1/2 trial of BCG (50mg/instillation) + N-803 (400 μg/instillation) in bladder & urothelial cancer, run by ImmunityBio, Inc., active and no longer recruiting.
Overview
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer is a phase 1/2 interventional study registered as NCT02138734 by ImmunityBio, Inc., with 369 participants enrolled, started 2014-07-21 and due to reach its primary completion in 2026-09-30. Interventions recorded: BCG (50mg/instillation) + N-803 (400 μg/instillation) and BCG (50mg/instillation).
Similar pages
not linked directly; found by shared links- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialSafety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialN-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma
Shares ImmunityBio and the tag pipeline.
- TrialStudy of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma
Shares ImmunityBio and the tag pipeline.